Either you do not have the newest version of Adobe Flash®, or you have JavaScript disabled.

Please ensure you have these capabilities.

RELEASES

  • For further information contact:
    Fred Iannotti
    802-888-0085
    fiannotti@planningsource.com

    Scientists Who Developed "Multispectral" Identafi 3000 Ultra Deliver NIH Paper on New Optical Device That Images Cancer – Two Trimira Cancer Researchers' Work on Optical Spectroscopy Led to World's First Three-Wavelength Oral Cancer Detection Device

    BETHESDA, Oct. 16, 2009 — Two Texas cancer researchers who were instrumental in developing the science behind Trimira® LLC's Identafi® 3000 ultra — the world's first and only oral cancer detection device that illuminates with three wavelengths of brilliant white, violet, and green-amber light — presented two papers at the "Inter-Institute Workshop on Optical Diagnostic and Biophotonic Methods from Bench to Bedside" held October 1-2 at the National Institutes of Health (NIH) in Bethesda, Md.

    Identafi Is Only Device to Use "Multispectral" Technology

    The NIH workshop brought together experts in the diagnosis and treatment of several important health issues. The format included talks by leading experts in the biophotonic field, as well as panels of experts addressing the needs for fast cures and overcoming barriers to translational medicine. The NIH workshop was sponsored by SPIE (http://spie.org), an international society advancing light-based research.

    The presenters of paper NIH01-32 included Trimira® founder-scientists Dr. Ann M. Gillenwater, professor of the Head and Neck Surgery and Epidemiology Department, The University of Texas' M.D. Anderson Cancer Center, Houston, and Dr. Rebecca Richards-Kortum of the Optical Spectroscopy and Imaging Laboratory, Rice University, Houston. Other co-authors were Mark C. Pierce, Timothy J. Muldoon, Robert Kester, Tomasz Tkaczyk, and Sharmila Anandasabapathy. Richards-Kortum and Gillenwater helped develop the breakthrough optical system for cancer early detection called "multispectral" spectroscopy. Created exclusively for intraoral use, the new cordless Identafi® 3000 ultra unit is lightweight, portable, and ergonomically shaped for dentists, periodontists, oral surgeons, otolaryngologists, and primary-care physicians.

    Identafi® 3000 ultra
    www.trimira.net/identafi

    Identafi® 3000 ultra's patented technology minimizes false positives and reveals abnormalities in oral tissue missed by the naked eye. Unlike other methods, Identafi® 3000 ultra empowers doctors and dentists to pinpoint biochemical and morphological changes in cells. It represents a quantum leap in the visualization of oral cancer or premalignant dysplasia. The multispectral technology not only is effective in screening oral cancers but also in diagnosing cervical, skin, gastrointestinal, and bladder cancers.

    The abstract of the NIH paper on the SPIE website details the development of a new optical imaging device contained within a small gauge needle, which can be inserted into tissue and acquire images with sub-cellular resolution in real-time. The device is based around wide-field epi-fluorescence imaging through a coherent fiber-optic bundle.

    "Integrated Optical Needle (ION) for Cellular and Molecular Imaging of Cancer"
    http://tinyurl.com/yh24n7z

    Gillenwater and Richards-Kortum also participated in the presentation of a second paper at the NIH workshop. Titled "Molecular-Specific Optical Imaging and Spectroscopy to Aid in Early Detection and Margin Prediction for Oral Dysplasia and Cancer," paper NIH01-63's co-authors were Kelsey J. Rosbach and Michelle Williams.

    About Trimira LLC

    Trimira® LLC is venture capital-funded by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Other Trimira® LLC sister subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm® LLC, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm® LLC's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.

    Visit Trimira® LLC at: http://www.trimira.net/





Animations

Identafi® Technology



Identafi® 3000 ultra Process



Screening Results



Training